DEA Rescheduling Objection Deadline Arrives Monday, August 18

Objection Deadline Triggers Potential ALJ Review

Any party who files a timely objection by Monday's deadline may request an administrative law judge (ALJ) hearing under 21 CFR §1308.44. The DEA must grant a hearing if the objection raises genuine issues of material fact regarding the rescheduling proposal. Miss the 11:59 PM Eastern cutoff on August 18, and you forfeit the right to request a hearing—even if your objection is substantive.

The DEA published its Notice of Proposed Rulemaking (NPRM) on May 21, 2026, proposing to move cannabis and its derivatives from Schedule I (reserved for substances with no accepted medical use) to Schedule III, which permits prescription use and allows manufacturers to deduct ordinary business expenses under IRC §162. More than 43,000 submissions have hit the Federal Register docket during the 90-day comment period.

Schedule III Classification and IRC §280E Relief

Rescheduling to Schedule III would eliminate the IRC §280E tax penalty that currently prohibits cannabis businesses from deducting cost of goods sold and operating expenses. State-licensed cannabis operators now pay effective federal tax rates exceeding 70 percent because §280E disallows deductions for businesses trafficking in Schedule I or II controlled substances. Schedule III status would allow standard business deductions, cutting effective rates to the corporate statutory rate of 21 percent.

State-level legality doesn't change. Cannabis would remain federally controlled and subject to DEA licensing, manufacturing quotas, and distribution restrictions under 21 USC §823(a). Operators would need DEA registrations to handle Schedule III substances lawfully.

Objection Standards Under 21 CFR §1308.44

To compel an ALJ hearing, an objection must identify specific factual disputes material to the rescheduling determination. The regulation requires objectors to state with particularity the factual issues in dispute and provide supporting evidence or affidavits. Generic policy disagreements won't cut it. Unsupported assertions don't meet the threshold either.

The DEA evaluates objections using the eight-factor test established in 21 USC §811(c), which examines abuse potential, scientific evidence of pharmacological effect, current scientific knowledge, history and pattern of abuse, scope and significance of abuse, and risk to public health. The agency's proposal leans heavily on the Department of Health and Human Services' August 2023 scheduling recommendation, which concluded that cannabis has a lower abuse potential than Schedule I or II substances and an accepted medical use in the United States.

Who Has Filed Objections

Trade groups, state attorneys general, and anti-legalization organizations have submitted formal objections citing concerns over pediatric access, impaired driving, and international treaty obligations. Smart Approaches to Marijuana (SAM) filed a 47-page objection arguing that rescheduling conflicts with the Single Convention on Narcotic Drugs. The National Cannabis Industry Association (NCIA) submitted comments supporting rescheduling but requesting clarification on interstate commerce rules and whether state-licensed operators may obtain DEA registrations without federal preemption challenges.

Timeline After Monday's Deadline

The DEA will review objections and determine whether to proceed with a final rule or convene an ALJ hearing. If no objections meet the §1308.44 threshold, the agency may publish a final rule as early as October 2026. Grant a hearing, and the process extends by 12 to 18 months. Administrative law proceedings under the Controlled Substances Act historically take 14 months from notice to final agency decision, based on prior rescheduling cases involving MDMA and synthetic cannabinoids.

For full background on this proceeding, see the CannIntel topic hub on DEA rescheduling.

What Operators Should Watch

Cannabis businesses should monitor the docket for the DEA's post-deadline announcement on whether it'll grant any hearing requests. That determination, typically issued 30 to 45 days after the comment period closes, will clarify whether the rescheduling timeline extends into 2027 or whether a final rule may take effect before year-end 2026. Operators should also track IRS guidance on the effective date of §280E relief, which may not align precisely with the DEA's final rule publication date depending on how Treasury interprets the statutory trigger.